ZALTRAP® for second line treatment of metastatic CRC

April 15th, 2012

ZALTRAP® (Aflibercept) is a soluble fusion protein that is capable of binding with high affinity to pro-angiogenic factors such as all VEGF-A isoforms, VEGF-B, and PlGF. This is unlike bevacizumab, which is a monoclonal antibody that only targets all isoforms of VEGF-A.  In the VELOUR trial, second-line chemotherapy in combination with ZALTRAP® (Aflibercept) demonstrated significant improvement in the progression-free survival  as well as overall survival compared to chemotherapy alone. This benefit was seen irrespective of prior bevacizumab therapy. This data was presented at the 13th ESMO world congress.

Regorafenib improves survival in advanced CRC

April 15th, 2012

The CORRECT trial is a randomized phase III  study which demonstrated improved survival with Regorafenib, an oral multikinase inhibitor when compared to placebo, in individuals with advanced colorectal cancer, who had progressed on all available standard therapies. This important study gives a new option for individuals with advanced colorectal cancer. Additional data will be presented at ASCO 2012 meeting.

CLEOPATRA Trial in Breast Cancer

April 10th, 2012

In this Phase III trial involving first line treatment of patients with HER-2 positive metastatic breast cancer,  the addition of Pertuzumab (an anti-HER-2 humanized monoclonal antibody that inhibits receptor dimerization) to a combination of Trastuzumab and Docetaxel significantly prolonged progression-free survival, without increase in cardiotoxicity when compared to Trastuzumab and Docetaxel alone. It appears that Pertuzumab complements Trastuzumab in targeting HER-2 receptor.

These findings from the CLEOPATRA trial have demonstrated that comprehensive  HER-2 blockade may result in improved outcomes for patients with breast cancer  over expressing HER-2.

The original article was published in the January 2012  issue of the NEJM.